Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Aug 13, 2025
With the clearance of the U.S. IND, initiation of the U.S. clinical trial of AXN-2510/IMM2510 (“‘2510”) anticipated before the end of 2025
Updated ‘2510 monotherapy data in squamous-NSCLC to be presented at IASLC’s 2025 World Conference on Lung Cancer (WCLC) by ImmuneOnco
Read more at globenewswire.com
